S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$517.93
+0.02 (+0.00 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$511.11
Now: $517.93
$523.03
50-Day Range
$470.09
MA: $493.85
$517.91
52-Week Range
$328.13
Now: $517.93
$664.64
Volume41,384 shs
Average Volume1.06 million shs
Market Capitalization$55.27 billion
P/E Ratio20.05
Dividend YieldN/A
Beta0.51
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals logo

MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

25th out of 67 stocks

Pharmaceutical Preparations Industry

11th out of 31 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000
Employees8,314

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$21.51 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Market Cap$55.27 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$517.93
+0.02 (+0.00 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 11.5% and is now trading at $517.93.
View which stocks have been most impacted by COVID-19
.

Is Regeneron Pharmaceuticals a buy right now?

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 8 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported $8.36 earnings per share for the quarter, missing the consensus estimate of $9.52 by $1.16. The biopharmaceutical company earned $2.29 billion during the quarter, compared to the consensus estimate of $2.09 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. Regeneron Pharmaceuticals's quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.67 earnings per share.
View Regeneron Pharmaceuticals' earnings history
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its board has authorized a share repurchase plan on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board of directors believes its stock is undervalued.

What price target have analysts set for REGN?

25 brokers have issued 12-month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $429.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $618.39 in the next year. This suggests a possible upside of 19.4% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 68, Pay $4.77M)
  • Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 61, Pay $3.98M)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 57, Pay $1.56M)
  • Dr. Andrew J. Murphy, Exec. VP of Research (Age 63, Pay $1.29M)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 48, Pay $1.46M)
  • Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
  • Mr. Gerald Underwood, Sr. VP of Technical Operations
  • Justin Holko, VP of Investor Relations
  • Mr. Joseph J. LaRosa, Exec. VP, Gen. Counsel & Sec. (Age 62)
  • Ms. Beth F. Holly, Sr. VP, Associate Gen. Counsel & Chief Compliance Officer

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.03%), Hexavest Inc. (0.02%), Traynor Capital Management Inc. (0.01%), Baldwin Brothers Inc. MA (0.01%), Louisiana State Employees Retirement System (0.01%) and Jacobs & Co. CA (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Central Bank & Trust Co., State of Alaska Department of Revenue, New England Research & Management Inc., Mountain Capital Investment Advisors Inc, Sowell Financial Services LLC, Cypress Capital Group, and Raymond James Trust N.A.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Baldwin Brothers Inc. MA, NuWave Investment Management LLC, Traynor Capital Management Inc., Jacobs & Co. CA, IFM Investors Pty Ltd, First Hawaiian Bank, and Redpoint Investment Management Pty Ltd.
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $517.93.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $55.27 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,314 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.